Epstein-Barr Virus Associated LymphomaWGc-043NCT06788600
Mechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory Lymphoma
An observational study of Epstein-Barr Virus Associated Lymphoma, run by Ruijin Hospital at 1 site in China.
Trial summary
This exploratory study, based on a pharmaceutical company-initiated clinical trial, aims to investigate the therapeutic effects of the EBV mRNA vaccine (WGc-043 injection) in treating EBV-positive relapsed or refractory lymphoma. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Epstein-Barr Virus Associated Lymphoma
- What is being tested?
- EBV mRNA vaccine (WGc-043)
- Type of treatment
- Vaccines
- How many people
- 15 participants
- Where
- 1 siteChina
- Study dates
- 1 Apr 2025to 31 Oct 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with EBV-positive relapsed or refractory lymphoma
Who may be able to join
- Male or female patients aged 18 to 75 years (inclusive).
- Histologically or cytologically diagnosed as relapsed or refractory EBV-positive lymphoma (confirmed by in situ hybridization (ISH) or fluorescence in situ hybridization (FISH) showing EBER positivity in tumor tissue) that has failed standard treatment and lacks effective treatment options. This includes, but is not limited to, NK/T-cell lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), or other Peripheral T-cell Lymphomas (PTCL).Relapse is defined as the appearance of new lesions in the primary site or elsewhere after achieving complete remission (CR).
- (1)Refractory is defined by any of the following conditions: No partial response (PR) after ≥2 cycles of treatment. No CR after ≥4 cycles of treatment. No complete remission (CR) after autologous hematopoietic stem cell transplantation.
- If the best response or reason for discontinuation is progressive disease (PD), no cycle number requirements apply.
- (2)Prior treatment must include:
- Relapsed/Refractory DLBCL: Must have received at least second-line systemic therapy.
Show all 22Show fewer
- Relapsed/Refractory Peripheral T-cell Lymphoma: Must have received at least first-line systemic therapy.
- Relapsed/Refractory NK/T-cell Lymphoma: Must have received a regimen based on L-asparaginase (I/II stage diseases as per the nasal NK/T-cell lymphoma CA staging system must have also received radiotherapy).
- 3.Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-2 points. 4.Expected survival ≥3 months. 5.At least one measurable lesion as defined by the Lymphoma Classification (2014 version), with measurable lesions defined as:
- A lymph node lesion with a maximum long diameter >15 mm on enhanced CT, MRI, or PET-CT.
- An extranodal lesion with a maximum long diameter >10 mm. 6.Adequate organ function as evidenced by the following criteria:
- <!-- -->
- No use of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human erythropoietin, recombinant human thrombopoietin, or blood component transfusion within 14 days prior to screening. Hemoglobin ≥80 g/L; neutrophil count >1.0 × 10^9/L; platelet count ≥75 × 10^9/L.
- Total bilirubin ≤1.5× upper limit of normal (ULN); if liver metastasis or Gilbert's syndrome present, total bilirubin ≤3× ULN.
- ALT or AST ≤2.5× ULN; if liver metastasis, ALT or AST ≤5× ULN.
- Serum creatinine (SCr) ≤1.5× ULN or creatinine clearance ≥50 mL/min (Cockcroft-Gault formula).
- Prothrombin time (PT), International Normalized Ratio (INR) ≤1.5× ULN (unless using warfarin for anticoagulation).
- Cardiac Doppler ultrasound evaluation: Left ventricular ejection fraction (LVEF) ≥50%.
- If the investigator considers any of the above parameters below the study's lower limit due to disease progression, the patient's inclusion can be discussed with the sponsor and the CRO's medical team.
- 7.No plans for pregnancy during the treatment period. Female patients of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the trial and for 4 months after treatment.
- 8.Able to understand and voluntarily sign a written informed consent form before the trial.
- 9.Able to communicate well with the investigator and adhere to the protocol for completing the trial.
Who cannot join
- Exclusion Criteria
- Patients with a history of other tumors, except for skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, in situ cervical cancer, gastrointestinal mucosal carcinoma, or other malignancies considered acceptable by the investigator, provided these were treated and have not recurred within the last 5 years.
- Known to have aggressive NK-cell leukemia; central nervous system (CNS) lymphoma or CNS metastases; or associated hemophagocytic syndrome.
- Known to have poorly controlled cardiac clinical symptoms or diseases, such as NYHA Class II heart failure or higher (see Appendix 4, section 16.4), unstable angina, myocardial infarction within the past 6 months, or clinically significant and treatable supraventricular or ventricular arrhythmias.
- Any active autoimmune disease or history of autoimmune diseases, including but not limited to immune-related neurological diseases, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barré syndrome, myasthenia gravis, systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, autoimmune hepatitis, toxic epidermal necrolysis (TEN), or Stevens-Johnson syndrome (except for Type 1 diabetes managed with stable doses of insulin).
- Any uncontrolled clinical disease (e.g., respiratory, circulatory, digestive, neurological, hematological, urogenital, endocrine diseases) or mental illness (e.g., depression, schizophrenia) or other significant illnesses that, in the investigator's assessment, could hinder informed consent, interfere with the interpretation of trial results, pose risks to the subject from participation, or otherwise affect the trial's objectives.
Show all 26Show fewer
- History of interstitial lung disease or suspected interstitial lung disease; or presence of pulmonary abnormalities that may interfere with the detection or management of potential drug-related pulmonary toxicity during the trial.
- Allergies to the investigational drug (including any excipients). A history of severe allergic reactions to any drugs, foods, or vaccines, such as anaphylactic shock, allergic laryngeal edema, allergic dyspnea, allergic purpura, thrombocytopenic purpura, or local allergic necrotizing reactions (Arthus reactions).
- Any abnormalities at the injection site or permanent body art (e.g., tattoos) that the investigator believes may hinder observation of local reactions at the injection site.
- Contraindications to intramuscular injection (see Appendix 5, section 16.5).
- Less than 4 weeks since the last anti-tumor treatment (radiotherapy, chemotherapy, targeted therapy, immunotherapy, or local-regional therapy) or less than 2 weeks since palliative radiotherapy; patients with treatment-related adverse reactions (excluding hair loss) from previous anti-tumor therapy that have not recovered to NCI CTCAE ≤ 1 level.
- Previous organ transplantation or allogeneic hematopoietic stem cell transplantation.
- Systemic treatment with corticosteroids (>10 mg/day of prednisone or equivalent dose of other glucocorticoids) or other immunosuppressants within 14 days prior to the first dose of vaccine. However, inhaled or local use of steroids and adrenal hormone replacement at doses ≤10 mg/day of prednisone in the absence of active autoimmune disease is permitted.
- Receipt of an mRNA vaccine or similar nanoparticle delivery drugs (e.g., LNP) within 6 months prior to the first dose of vaccine.
- Receipt of live vaccines, attenuated live vaccines, or inactivated vaccines within 4 weeks prior to the first dose of vaccine.
- Previous administration of therapeutic vaccines or cellular immunotherapy for anti-tumor treatment.
- Participation in other clinical trials of drugs or devices within 3 months prior to screening.
- Blood donation or significant blood loss (>450 mL) within 3 months prior to screening.
- Major surgery within 4 weeks prior to screening (catheter placement or small biopsies as required by the protocol are not exclusion criteria), or if the impact of surgery or trauma has not resolved within 14 days prior to enrollment.
- History of substance abuse or known medical, psychological, or social conditions, such as a history of alcohol or drug abuse.
- Known infections with hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), or syphilis, or positive screening for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVAb), HIV antibody, or treponemal antibody (TP) at screening:
- HBsAg(+) or HBcAb(+), with HBV DNA copy number ≥2000 IU/mL (or above the lower limit of positive detection at the study center);
- HCVAb positive, with HCV RNA ≥ ULN at the study center.
- Patients with active tuberculosis (TB) (those suspected of having active TB must undergo chest X-ray, sputum tests, and exclude active TB through clinical symptoms and signs) or a history of active TB; or severe acute or chronic infections requiring systemic treatment.
- Pregnant or breastfeeding women.
- Any other factors that the investigator believes make the subject unsuitable for participation in this trial.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Ruijin Hospital
Shanghai, Shanghai Municipality, 200020
Weili Zhao, +862164370045, zwl_trial@163.com
About this study
Official title: An EBV mRNA Vaccine (WGc-043 Injection) in Patients With EB Virus-positive Relapsed or Refractory Lymphoma: A Phase I Clinical Trial Assessing the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Anti-tumor Activity
This exploratory study, based on a pharmaceutical company-initiated clinical trial, aims to investigate the therapeutic effects of the EBV mRNA vaccine (WGc-043 injection) in treating EBV-positive relapsed or refractory lymphoma. The study explores the mechanism of the EBV mRNA vaccine (WGc-043 injection) within the tumor microenvironment in EBV-positive lymphoma, elucidating the vaccine's inhibitory effects on EBV. This research will provide a theoretical foundation for the application of mRNA vaccines, either alone or in combination with other immunotherapies, in the treatment of EBV-positive lymphoma.
- Conditions
- Epstein-Barr Virus Associated Lymphoma
- Being tested
- EBV mRNA vaccine (WGc-043)
- Keywords
- relapsed or refractory lymphoma, Epstein-Barr virus mRNA vaccine, Epstein-Barr virus-positive lymphoma
- Medical subject headings
- Recurrence, Lymphoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EBV mRNA vaccine (WGc-043)Drug
Each subject will be infused with EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose.
The specific dose of mRNA vaccine will be determined according to the experimental group.
| Study group | Role | What they receive |
|---|---|---|
| EBV mRNA vaccine infusion with a dose of 100 µg | Drug: EBV mRNA vaccine (WGc-043) Patients will receive a 100 µg dose of the EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose. Receives: Drug: EBV mRNA vaccine (WGc-043) | |
| EBV mRNA vaccine infusion with a dose of 200 µg | Drug: EBV mRNA vaccine (WGc-043) Patients will receive a 200 µg dose of the EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose. Receives: Drug: EBV mRNA vaccine (WGc-043) | |
| EBV mRNA vaccine infusion with a dose of 300 µg | Drug: EBV mRNA vaccine (WGc-043) Patients will receive a 300 µg dose of the EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose. Receives: Drug: EBV mRNA vaccine (WGc-043) | |
| EBV mRNA vaccine infusion with a dose of 400 µg | Drug: EBV mRNA vaccine (WGc-043) Patients will receive a 400 µg dose of the EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose. Receives: Drug: EBV mRNA vaccine (WGc-043) |
What is being measured
The primary outcome is the main question the study is designed to answer.
ScRNA-seq profiles of tumor tissues before and after injection
Analysis of changes in the TME during treatment by comparing scRNA-seq profiles of tumor tissues before and after injection.
Measured: If the patient receives personalized treatment, safety follow-up will be conducted 28 days after the last infusion; if not, safety follow-up will be conducted 28 days after the 5th dose.
Clinical data from patients with disease remission (CR/PR) and those without remission (SD/PD)
Identification of key molecular mechanisms and immune cell components associated with treatment efficacy by comparing data from patients with disease remission (CR/PR) and those without remission (SD/PD).
Measured: If the patient receives personalized treatment, safety follow-up will be conducted 28 days after the last infusion; if not, safety follow-up will be conducted 28 days after the 5th dose.
Secondary outcomes (3)
Proportions of different immune cell types in tumor tissues from subjects with varying disease remission statuses.
(1) Identification of immune cells associated with the formation of immune memory by comparing the proportions of different immune cell types in tumor tissues from subjects with varying disease remission statuses. The molecular mechanisms underlying this process will be explored through gene expression profiling, focusing on key immune cell components and molecular pathways related to T cell memory formation.
Measured: If the patient receives personalized treatment, safety follow-up will be conducted 28 days after the last infusion; if not, safety follow-up will be conducted 28 days after the 5th dose.
Gene expression profiling in tumor tissues from subjects with varying disease
The molecular mechanisms underlying this process will be explored through gene expression profiling, focusing on key immune cell components and molecular pathways related to T cell memory formation. Identification of endogenous tumor factors associated with immune chemotaxis, T cell activation, and immune escape through correlation analysis with tumor cell characteristics, molecular genetic alterations, and oncogenic pathways.
Measured: If the patient receives personalized treatment, safety follow-up will be conducted 28 days after the last infusion; if not, safety follow-up will be conducted 28 days after the 5th dose.
Molecular biological changes in EBV in peripheral blood samples before and after EBV mRNA vaccine injection
Analysis of molecular biological changes in EBV in peripheral blood samples before and after EBV mRNA vaccine injection, focusing on changes in genes, proteins, and other molecular markers.
Measured: Time Frame: If the patient receives personalized treatment, safety follow-up will be conducted 28 days after the last infusion; if not, safety follow-up will be conducted 28 days after the 5th dose.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2025
- Study start1 Apr 2025 (estimated)
- Primary completion31 Oct 2026 (estimated)
- Study completion31 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Epstein-Barr Virus Associated LymphomaStudies of the same condition, open and under way.
- More trials run by Ruijin HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ruijin Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zhao Weili, Ruijin Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06788600
- Sponsor's protocol ID
- mRNAvaccine-WGc-043
- Acronym
- WGc-043
- Status last verified
- Jan 2025
- First submitted
- 13 Jan 2025
- Last updated
- 2 Apr 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An EBV mRNA Vaccine (WGc-043 Injection) in Patients With EB Virus-positive Relapsed or Refractory Lymphoma: A Phase I Clinical Trial Assessing the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Anti-tumor Activity
- ClinicalTrials.gov ID
- NCT06788600
- Acronym / sponsor ID
- WGc-043 / mRNAvaccine-WGc-043
- Conditions
- Epstein-Barr Virus Associated Lymphoma
- Keywords
- relapsed or refractory lymphoma, Epstein-Barr virus mRNA vaccine, Epstein-Barr virus-positive lymphoma
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Ruijin HospitalUniversity, hospital or other
- Study start
- 1 Apr 2025 (estimated)
- Primary completion
- 31 Oct 2026 (estimated)
- Study completion
- 31 Oct 2026 (estimated)
- First posted
- 23 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This exploratory study, based on a pharmaceutical company-initiated clinical trial, aims to investigate the therapeutic effects of the EBV mRNA vaccine (WGc-043 injection) in treating EBV-positive relapsed or refractory lymphoma. The study explores the mechanism of the EBV mRNA vaccine (WGc-043 injection) within the tumor microenvironment in EBV-positive lymphoma, elucidating the vaccine's inhibitory effects on EBV. This research will provide a theoretical foundation for the application of mRNA vaccines, either alone or in combination with other immunotherapies, in the treatment of EBV-positive lymphoma.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| EBV mRNA vaccine infusion with a dose of 100 µg | – | Drug: EBV mRNA vaccine (WGc-043)Drug: EBV mRNA vaccine (WGc-043) Patients will receive a 100 µg dose of the EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose. |
| EBV mRNA vaccine infusion with a dose of 200 µg | – | Drug: EBV mRNA vaccine (WGc-043)Drug: EBV mRNA vaccine (WGc-043) Patients will receive a 200 µg dose of the EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose. |
| EBV mRNA vaccine infusion with a dose of 300 µg | – | Drug: EBV mRNA vaccine (WGc-043)Drug: EBV mRNA vaccine (WGc-043) Patients will receive a 300 µg dose of the EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose. |
| EBV mRNA vaccine infusion with a dose of 400 µg | – | Drug: EBV mRNA vaccine (WGc-043)Drug: EBV mRNA vaccine (WGc-043) Patients will receive a 400 µg dose of the EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with EBV-positive relapsed or refractory lymphoma
Key inclusion criteria (22 listed)
- Male or female patients aged 18 to 75 years (inclusive).
- Histologically or cytologically diagnosed as relapsed or refractory EBV-positive lymphoma (confirmed by in situ hybridization (ISH) or fluorescence in situ hybridization (FISH) showing EBER positivity in tumor tissue) that has failed standard treatment and lacks effective treatment options. This includes, but is not limited to, NK/T-cell lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), or other Peripheral T-cell Lymphomas (PTCL).Relapse is defined as the appearance of new lesions in the primary site or elsewhere after achieving complete remission (CR).
- (1)Refractory is defined by any of the following conditions: No partial response (PR) after ≥2 cycles of treatment. No CR after ≥4 cycles of treatment. No complete remission (CR) after autologous hematopoietic stem cell transplantation.
- If the best response or reason for discontinuation is progressive disease (PD), no cycle number requirements apply.
- Relapsed/Refractory DLBCL: Must have received at least second-line systemic therapy.
Key exclusion criteria (26 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EBV mRNA vaccine (WGc-043)Each subject will be infused with EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose. The specific dose of mRNA vaccine will be determined according to the experimental group. | Drug | EBV mRNA vaccine infusion with a dose of 100 µg, EBV mRNA vaccine infusion with a dose of 200 µg, EBV mRNA vaccine infusion with a dose of 300 µg, EBV mRNA vaccine infusion with a dose of 400 µg |
Primary outcome
ScRNA-seq profiles of tumor tissues before and after injection
Time frame: If the patient receives personalized treatment, safety follow-up will be conducted 28 days after the last infusion; if not, safety follow-up will be conducted 28 days after the 5th dose.
Analysis of changes in the TME during treatment by comparing scRNA-seq profiles of tumor tissues before and after injection.
Clinical data from patients with disease remission (CR/PR) and those without remission (SD/PD)
Time frame: If the patient receives personalized treatment, safety follow-up will be conducted 28 days after the last infusion; if not, safety follow-up will be conducted 28 days after the 5th dose.
Identification of key molecular mechanisms and immune cell components associated with treatment efficacy by comparing data from patients with disease remission (CR/PR) and those without remission (SD/PD).
3 secondary outcomes
Proportions of different immune cell types in tumor tissues from subjects with varying disease remission statuses.
Time frame: If the patient receives personalized treatment, safety follow-up will be conducted 28 days after the last infusion; if not, safety follow-up will be conducted 28 days after the 5th dose.
Gene expression profiling in tumor tissues from subjects with varying disease
Time frame: If the patient receives personalized treatment, safety follow-up will be conducted 28 days after the last infusion; if not, safety follow-up will be conducted 28 days after the 5th dose.
Molecular biological changes in EBV in peripheral blood samples before and after EBV mRNA vaccine injection
Time frame: Time Frame: If the patient receives personalized treatment, safety follow-up will be conducted 28 days after the last infusion; if not, safety follow-up will be conducted 28 days after the 5th dose.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Apr 2025.
- Individual participant dataSharing planned: No
Related trials for Epstein-Barr Virus Associated Lymphoma
RecruitingObservational study
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Chronic Myeloproliferative Disorders, Leukemia
Active, not recruitingPhase 2
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Active, not recruitingObservational study
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia
RecruitingPhase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications
RecruitingPhase 1
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Epstein-Barr Virus Associated Lymphoma, run by Ruijin Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 22 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Weili Zhao (+862164370045, zwl_trial@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
ScRNA-seq profiles of tumor tissues before and after injection (time frame: If the patient receives personalized treatment, safety follow-up will be conducted 28 days after the last infusion; if not, safety follow-up will be conducted 28 days after the 5th dose.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2025.